Ces radiol. 2017, 71(2):151-154 | DOI: 10.55095/CesRadiol2017/020

Symptomatic occlusion of mesenteric vein solved by implantation of self-expanding stentCase report

Jan Kaván1, Jiří Křivánek1, Patrik Matras1, Lubomíra Forejtová1, Tomáš Padrta1, Eva Sedláčková2
1 Radiodiagnostická klinika 1. LF UK a VFN, Praha
2 Onkologická klinika 1. LF UK a VFN, Praha

The aim of this article is to present a case study of a patient with symptomatic occlusion of superior mesenteric vein caused by external compression of the vein by mesenteric masses (carcinoid metastases). The resulting venous hypertension was one of the causes of intractable ascites. As the surgical risk was too high, we were asked to perform a transhepatic endovascular recanalization of the superior mesenteric vein with stent placement. Almost immediately after the recanalization the formation of the ascites slowed down and the frequency of necessary paracenteses decreased threefold. The follow-up CT after 11 months after the stent placement shows patent superior mesenteric vein and the frequency of paracenteses remains prolonged.

Keywords: stent placement, superior mesenteric vein, transhepatic endovascular approach

Accepted: March 30, 2017; Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaván J, Křivánek J, Matras P, Forejtová L, Padrta T, Sedláčková E. Symptomatic occlusion of mesenteric vein solved by implantation of self-expanding stent. Ces radiol. 2017;71(2):151-154. doi: 10.55095/CesRadiol2017/020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sarin SK, Khanna R. Non-cirrhotic portal hypertension. Clin Liver Dis 2014; 18: 451-476. Go to original source... Go to PubMed...
    2. Shneider BL, Bosch J, de Franchis R, et al. Expert Panel of the Children's Hospital of Pittsburgh of UPMC. Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transpl 2012; 16: 426-437. Go to original source... Go to PubMed...
    3. Klener P, et al. Vnitřní lékařství. Praha: Galén 1999; 532-533.
    4. Hellman P, Hessman O, Åkerström G, et al. Stenting of the Superior Mesenteric Vein in Midgut Carcinoid Disease with Large Mesenteric Masses. World Journal of Surgery 2010; 34(6): 1373-1379. Go to original source... Go to PubMed...
    5. Kelay A, Morgan-Rowe L, Constantinou J, Malago M, Ivancev K. Retrograde Stenting Under Transmesenteric Angiographic Guidance of an Occluded Superior Mesenteric Vein to Treat Life-Threatening Hemorrhage. Annals of Vascular Surgery 2016; 31: 209.e11-209.e15. Go to original source... Go to PubMed...
    6. Beyer LP, Wohlgemuth WA, Uller W, et al. Percutaneous treatment of symptomatic superior mesenteric vein stenosis using self-expanding nitinol stents. European Journal of Radiology [online] 2015; 84(10): 1964-1969. Go to original source... Go to PubMed...
    7. Bosch J, et al. Effects of somatostatin in patients with portal hypertension. J Hepatol 1988; 29(2-3): 99-102. Go to original source... Go to PubMed...
    8. Sieber C. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion. Clinical Pharmacology & Therapeutics 2004; 75(1): 70-79. Go to original source... Go to PubMed...
    9. Schiedermaier P, Harrison P, Arthur M, et al. Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis. Digestion 2002; 65(1): 56-60. Go to original source... Go to PubMed...
    10. Schiedermaier P, Koch L, Stoffel-Wagner B, Layer G, Sauerbruch T. Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. Alimentary Pharmacology and Therapeutics 2003; 18(8): 777-784. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content